A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

No randomized clinical trials have directly compared empagliflozin with dapagliflozin for type 2 diabetes, so investigators conducted a large comparative effectiveness study examining kidney outcomes.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Empagliflozin (Jardiance, BI 10773, Gibtulio, Jardianz) is an ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

Among the first 10 drugs selected for price negotiations under the 2022 Inflation Reduction Act, cardiometabolic medications ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...